Audentes Therapeutics, Inc. Reports Unaudited Earnings Results for Third Quarter and Nine Months Ended September 30, 2018
Audentes Therapeutics, Inc. reported unaudited earnings results for third quarter and nine months ended September 30, 2018. For the quarter, the company’s net loss was $36,291,000 or $0.97 per basic and diluted compared to $25,009,000 or $0.88 per basic and diluted for the same period a year ago. Loss from operations was $37,735,000 compared to $25,210,000 for the same period a year ago.
For the nine months, the company’s net loss was $93,229,000 or $2.57 per basic and diluted compared to $65,863,000 or $2.59 per basic and diluted for the same period a year ago. Loss from operations was $96,774,000 compared to $66,296,000 for the same period a year ago.